Evaluation of the Kinetics of mRNA Expression After Two Doses of GSK Biologicals' Candidate Tuberculosis (Tuberculosis) Vaccine GSK 692342 in Healthy Adults
GSK's candidate tuberculosis vaccine, GSK 692342, aims to enhance immune response through mRNA expression profiling. Given the global burden of tuberculosis, particularly in developing regions, successful development could position GSK favorably in the vaccine market. The competitive landscape includes established vaccines like BCG and emerging candidates from other biopharma companies. Diligence should focus on regulatory pathways, potential partnerships for distribution, and the evolving landscape of tuberculosis treatment and prevention strategies.
Indication: Tuberculosis
Modality: protein therapy
Target: mRNA expression modulation related to tuberculosis immunity
Sponsor: GlaxoSmithKline
Source URL: ClinicalTrials.gov
Source updated: Mar 22, 2019
Ingested: Jun 17, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: mRNA expression modulation related to tuberculosis immunity
View original source fields
Condition raw: Tuberculosis
Condition normalized: Tuberculosis
Modality raw: protein therapy
Modality normalized: protein therapy
Target raw: mRNA expression modulation related to tuberculosis immunity
Target normalized: mRNA expression modulation related to tuberculosis immunity